MMI North America

Medical Microinstruments, Inc. (MMI) is dedicated to advancing robotic technology for microsurgery, enabling surgeons to perform complex procedures with enhanced precision and control. Founded in 2015 near Pisa, Italy, MMI develops the Symani® Surgical System, a first-of-its-kind robotic platform for open, soft tissue micro-level surgery, addressing unmet patient needs in microvascular, lymphatic, and nerve repair. The system is FDA authorized in the U.S. and CE marked in Europe, with a mission to expand treatment options and improve clinical outcomes worldwide. MMI's innovations have been recognized as a TIME Best Invention of 2024, and the company has achieved regulatory approvals in 35 countries, with a significant expansion into Asia-Pacific markets including Japan, Hong Kong, Malaysia, New Zealand, and Taiwan. The company collaborates with leading distributors such as Gunze Medical Limited and the Synektik Group to broaden global access. MMI's technology addresses microvascular repair, lymphatic repair, peripheral nerve repair, and other complex microsurgical procedures, with clinical applications spanning breast cancer reconstruction, lymphedema, head & neck cancer, trauma, and ophthalmic surgeries. The Symani Surgical System features the world's smallest wristed microinstruments, tremor reduction, and motion scaling, enabling highly precise microsurgical interventions. The company actively participates in industry conferences, clinical research, and educational initiatives to promote the adoption of robotic microsurgery. MMI is backed by prominent investors including Fidelity, Andera Partners, Deerfield Management, and others, and maintains a strong commitment to innovation, clinical excellence, and expanding treatment options for patients worldwide.